Company / Current Assets
Allogene Therapeutics, Inc. Current Assets History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$257.7M
FY2025
5-year range
$257.7M / $471.3M
FY2021-FY2025
Trend
-15.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Assets has declined for 4 consecutive years, from $471M in FY2021 to $258M in FY2025.
Based on SEC 10-K filings.
$258M in FY2025 with a 3-year CAGR of -18.1%.
Declined from $459M to $258M over the past 2 years.
Current Assets over time
Growth rates
- 3-Year CAGR
- -18.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Allogene Therapeutics, Inc.'s current assets has declined for 4 consecutive years.
- 3-year CAGR of -18.1%, indicating a declining trend.
- In FY2025, current assets decreased 15.0% year-over-year.
- Peak current assets was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.27 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $257.7M | -15.0% |
| FY2024 | $303.4M | -33.9% |
| FY2023 | $459.1M | -2.3% |
| FY2022 | $469.7M | -0.3% |
| FY2021 | $471.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026